Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
GO
Graves’ disease
Graves’ orbitopathy
RAI (radioiodine) ablation
TED
age
sex
thyroid eye disease (TED)
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
02
2023
accepted:
22
03
2023
medline:
24
4
2023
pubmed:
21
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
Severity of Graves' orbitopathy (GO) shows wide individual differences. For optimal treatment, it is important to be able to predict the natural course of the disease as accurate as possible to counteract with anti-inflammatory and surgical treatment. Therefore, we aimed to further elucidate the impact of sex, age and smoking on GO. We collected the clinical and demographic data of all patients of our tertiary referral center from January 2008 till December 2018 and analyzed it with descriptive statistics. Only patients with a complete data set were included in the further analysis. Odds ratio's for moderate-to-severe and sight-threatening GO in relation to age, sex and smoking were calculated by means of multivariate logistic regression models. We evaluated the data of 4260 patient with GO and complete data sets. Most of these were women (83%). There were no significant differences between male and female patients regarding smoking habits and thyroid treatment. Men were significantly older at initial manifestation of TED (51.8 vs. 49.9y, p<0.01) and showed significant more often severe stages (61% vs. 53%, p<0.0001). Therefore, they needed significantly more intense treatment with steroids, irradiation, orbital decompression and muscle surgery. In multivariate logistic regression analyses age (OR 0.97, 95% CI:0.97-0.98, p<0.0001), male sex (OR 1.64, 95% CI:1.38-1.9, p<0.0001), smoking (OR 1.19, 95% CI:1.04-1.36, p=0.01), Grave's disease (OR 1.55, 95% CI:1.26-1.90, p<0.0001) and history of radioiodine treatment (RAI) (OR 2.44, 95% CI:2.10-2.86, p<0.0001) showed an significant association with severe stages of GO. Our retrospective analysis showed once more that women are more often afflicted by GO. In contrast, men seem to be more severely afflicted and in need of anti-inflammatory and surgical treatments. This might be due to a different approach to the health system and resilience to GO specific symptoms, as well as previously described worse thyroid control. Estrogen mediated effects might also play a role as in other autoimmune diseases and should be subject of further trials. Besides the biological sex, smoking could again be confirmed as serious risk factor for severe GO. Of note, RAI was associated with more severe stages of GO, which should be subject to further investigation.
Identifiants
pubmed: 37082130
doi: 10.3389/fendo.2023.1160172
pmc: PMC10110835
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1160172Informations de copyright
Copyright © 2023 Oeverhaus, Winkler, Stähr, Daser, Bechrakis, Stöhr, Chen and Eckstein.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2018 Aug 30;8(1):13096
pubmed: 30166557
J Immunol. 2008 Sep 15;181(6):4397-405
pubmed: 18768899
Nat Rev Dis Primers. 2020 Jul 2;6(1):52
pubmed: 32616746
Clin Endocrinol (Oxf). 1993 Apr;38(4):367-72
pubmed: 8319368
J Endocrinol Invest. 2013 Jun;36(6):444-9
pubmed: 23587873
J Clin Endocrinol Metab. 2012 Jul;97(7):2325-32
pubmed: 22518849
J Neuroophthalmol. 2014 Jun;34(2):177-85
pubmed: 24821101
J Endocrinol Invest. 2018 Dec;41(12):1417-1423
pubmed: 29923059
Br J Ophthalmol. 2023 Jan 10;:
pubmed: 36627174
Endocr Rev. 1993 Dec;14(6):747-93
pubmed: 8119236
Clin Endocrinol (Oxf). 2001 Sep;55(3):283-303
pubmed: 11589671
Thyroid. 1997 Dec;7(6):885-9
pubmed: 9459632
J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9
pubmed: 23408569
J Clin Endocrinol Metab. 2015 Mar;100(3):1071-7
pubmed: 25485727
Croat Med J. 2011 Oct 15;52(5):615-21
pubmed: 21990079
Br Med J (Clin Res Ed). 1987 Sep 12;295(6599):634-5
pubmed: 3117268
Endocr Pract. 2021 Mar;27(3):245-253
pubmed: 33655885
Clin Ophthalmol. 2014 Jul 10;8:1295-300
pubmed: 25031528
Endocrinology. 2022 Dec 19;164(2):
pubmed: 36477465
Eur J Endocrinol. 2011 Dec;165(6):899-905
pubmed: 21908653
JAMA Ophthalmol. 2022 Jul 1;140(7):667-673
pubmed: 35588051
Lancet. 1990 May 26;335(8700):1261-3
pubmed: 1971331
Front Immunol. 2022 Jun 17;13:898138
pubmed: 35784325
Thyroid. 2022 Dec;32(12):1547-1558
pubmed: 36128805
J Clin Endocrinol Metab. 2000 Mar;85(3):1038-42
pubmed: 10720036
Horm Metab Res. 2015 Sep;47(10):727-34
pubmed: 26361259
J Clin Endocrinol Metab. 2016 Jul;101(7):2711-20
pubmed: 27055083
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67
pubmed: 34297684
Endocr Rev. 2003 Dec;24(6):802-35
pubmed: 14671007
Thyroid. 2010 Jul;20(7):785-93
pubmed: 20578895
Eye (Lond). 2007 Sep;21(9):1135-45
pubmed: 16980921
N Engl J Med. 1992 Jun 25;326(26):1733-8
pubmed: 1489388
Orphanet J Rare Dis. 2017 Apr 20;12(1):72
pubmed: 28427469
Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14
pubmed: 9302365
Eur J Endocrinol. 2002 Feb;146(2):153-61
pubmed: 11834423
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5391-5397
pubmed: 30452592
Horm Metab Res. 2021 Jul;53(7):435-443
pubmed: 34282595
Br J Ophthalmol. 1989 Aug;73(8):639-44
pubmed: 2765444
Arthritis Res Ther. 2019 Apr 2;21(1):85
pubmed: 30940202
Am J Ophthalmol. 1995 Oct;120(4):511-7
pubmed: 7573310
Ophthalmologe. 2020 Nov;117(11):1105-1111
pubmed: 32034469
Aust N Z J Med. 1985 Apr;15(2):258-61
pubmed: 3861168
Endocr Rev. 2000 Apr;21(2):168-99
pubmed: 10782363
J Clin Endocrinol Metab. 2006 Dec;91(12):4873-80
pubmed: 16968788
Korean J Ophthalmol. 2010 Oct;24(5):267-73
pubmed: 21052505
Korean J Ophthalmol. 2013 Dec;27(6):397-404
pubmed: 24311923
Horm Metab Res. 2015 Sep;47(10):773-8
pubmed: 26361262
J Clin Endocrinol Metab. 2016 Jun;101(6):2340-7
pubmed: 27043163